News Releases

Biogen to Present at the Stifel First Annual CNS Day

March 27, 2019 at 4:05 PM EDT

Cambridge, MA, - - Biogen Inc. (Nasdaq:BIIB) announced today that Michael Ehlers, M.D., Ph.D., executive vice president, research and development at Biogen, will present at the Stifel First Annual CNS Day. The webcast will be live on Monday, April 1, at 12:00 p.m. ET. To access the live webcast, please visit Biogen’s Investors section at http://investors.biogen.com/. An archived version of the webcast will be available following the presentation.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, MS and neuroimmunology, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also manufactures and commercializes biosimilars of advanced biologics. 

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

  
Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442